"id","name","instanceType","description","uuid:ID","text","label"
"Objective_1","OBJ1","Objective","Main objective","a3ae4347-f74b-4f3f-ace3-031b0fac204e","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",""
"Objective_2","OBJ2","Objective","Safety","2f877b5c-dd22-431c-b70a-218dea8c54aa","To document the safety profile of the xanomeline TTS.",""
"Objective_3","OBJ3","Objective","Behaviour","b88c283d-f146-4f93-9991-e0bedac565da","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.",""
